Radioligand therapies are showing compelling late-stage clinical results, but success in Phase 3 does not guarantee readiness for approval or commercial launch. This session will highlight the manufacturing and CMC challenges that often emerge too late, and discuss how early, scalable thinking is essential to bridge the gap between clinical success and real-world commercialization.